文献速递眼底病与葡萄膜炎

抗血管内皮生长因子药物注射后眼内炎症风险:一项Meta分析

RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS: A Meta-analysis.
PubMed 文献 · Retina · 2022-01-01

该Meta分析纳入14项随机对照试验、基线6759只眼,比较贝伐珠单抗、雷珠单抗、布西珠单抗和阿柏西普治疗新生血管性年龄相关性黄斑变性后眼内炎症的发生率。结果显示各药物间眼内炎和视网膜血管阻塞风险无差异,布西珠单抗较阿柏西普的广泛性眼内炎症和玻璃体混浊/飞蚊症发生率更高。作者认为布西珠单抗的风险获益特征需进一步研究。

要点

  • 各抗血管内皮生长因子药物间眼内炎和视网膜血管阻塞风险无差异。
  • 布西珠单抗较阿柏西普的广泛性眼内炎症风险更高(风险比=6.24,95%CI 1.40-27.90)。
  • 布西珠单抗较阿柏西普的玻璃体混浊/飞蚊症风险更高(风险比=1.64,95%CI 1.00-2.67)。

核心结论

  • 各玻璃体腔抗血管内皮生长因子药物之间严重威胁视力的眼内炎症结局风险无差异。
  • 布西珠单抗较阿柏西普的广泛性眼内炎症风险显著更高。
  • 作者认为结合其他近期安全性发现,布西珠单抗治疗新生血管性年龄相关性黄斑变性的风险获益特征需进一步研究。

研究设计与样本

  • 系统检索Ovid MEDLINE、Embase和Cochrane Central数据库2005年1月至2021年4月的文献。
  • 纳入比较贝伐珠单抗、雷珠单抗、布西珠单抗或阿柏西普玻璃体腔注射后眼内炎症的随机对照试验,研究对象为新生血管性年龄相关性黄斑变性。
  • 共筛选11460项研究,最终纳入14项随机对照试验、基线6759只眼,采用随机效应模型进行Meta分析。

主要发现

  • 各药物间眼内炎和视网膜血管阻塞风险无差异。
  • 与阿柏西普相比,布西珠单抗的广泛性眼内炎症发生率更高(风险比=6.24,95%置信区间=[1.40-27.90])。
  • 与阿柏西普相比,布西珠单抗的玻璃体混浊/飞蚊症发生率更高(风险比=1.64,95%置信区间=[1.00-2.67])。
  • 其他次要终点在各比较药物间无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This meta-analysis investigates the incidence of intraocular inflammation (IOI) after intravitreal antivascular endothelial growth factor injections in neovascular age-related macular degeneration. METHODS: A systematic search was performed on Ovid MEDLINE, Embase, and Cochrane Central from January 2005 to April 2021. Randomized controlled trials comparing IOI after intravitreal bevacizumab, ranibizumab, brolucizumab, or aflibercept in neovascular age-related macular degeneration were included. Primary outcomes were sight-threatening IOI, final best-corrected visual acuity, and change in best-corrected visual acuity from baseline. Secondary outcomes included the incidence of other IOI events. Meta-analysis was performed using a random-effects model. RESULTS: Overall, 11,460 unique studies were screened, of which 14 randomized controlled trials and 6,759 eyes at baseline were included. There was no difference between agents for the risk of endophthalmitis and retinal vascular occlusion. Compared with aflibercept, brolucizumab had a higher incidence of generalized IOI (risk ratio = 6.24, 95% confidence interval = [1.40-27.90]) and vitreous haze/floaters (risk ratio = 1.64, 95% confidence interval = [1.00-2.67]). There were no significant differences between comparators for other secondary end points. CONCLUSION: There was no difference in the risk of severe sight-threatening IOI outcomes between intravitreal antivascular endothelial growth factor agents. There was a significantly higher risk of generalized IOI after brolucizumab relative to aflibercept. Our results alongside other recent safety findings suggest the need for further investigation in the risk-benefit profile of brolucizumab for the treatment of neovascular age-related macular degeneration.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Patil NS, Dhoot AS, Popovic MM, et al. RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS: A Meta-analysis. Retina. 2022. PMID: 36269802. doi:10.1097/IAE.0000000000003582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。